| Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America JP Lalezari, K Henry, M O'Hearn, JSG Montaner, PJ Piliero, B Trottier, ... New England Journal of Medicine 348 (22), 2175-2185, 2003 | 1217 | 2003 |
| Quantitative image analysis of HIV-1 infection in lymphoid tissue AT Haase, K Henry, M Zupancic, G Sedgewick, RA Faust, H Melroe, ... Science 274 (5289), 985-989, 1996 | 733 | 1996 |
| Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection W Cavert, DW Notermans, K Staskus, SW Wietgrefe, M Zupancic, ... Science 276 (5314), 960-964, 1997 | 666 | 1997 |
| Severe premature coronary artery disease with protease inhibitors K Henry, H Melroe, J Huebsch, J Hermundson, C Levine, L Swensen, ... The Lancet 351 (9112), 1328, 1998 | 641 | 1998 |
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir … E DeJesus, JK Rockstroh, K Henry, JM Molina, J Gathe, S Ramanathan, ... The Lancet 379 (9835), 2429-2438, 2012 | 444 | 2012 |
| Primary infection with zidovudine-resistant human immunodeficiency virus type 1 A Erice, DL Mayers, DG Strike, KJ Sannerud, FE McCutchan, K Henry, ... New England Journal of Medicine 328 (16), 1163-1165, 1993 | 289 | 1993 |
| Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection ZQ Zhang, DW Notermans, G Sedgewick, W Cavert, S Wietgrefe, ... Proceedings of the National Academy of Sciences 95 (3), 1154-1159, 1998 | 282 | 1998 |
| Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study JM Molina, B Clotet, J van Lunzen, A Lazzarin, M Cavassini, K Henry, ... The lancet HIV 2 (4), e127-e136, 2015 | 265 | 2015 |
| Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities K Henry, H Melroe, J Huebesch, J Hermundson, J Simpson The Lancet 352 (9133), 1031-1032, 1998 | 260 | 1998 |
| Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS K Henry, H Cantrill, C Fletcher, BJ Chinnock, HH Balfour American journal of ophthalmology 103 (1), 17-23, 1987 | 253 | 1987 |
| Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results HL Cantrill, K Henry, NH Melroe, WH Knobloch, RC Ramsay, ... Ophthalmology 96 (3), 367-374, 1989 | 239 | 1989 |
| Blockade of HERG channels by HIV protease inhibitors BD Anson, JGR Weaver, MJ Ackerman, O Akinsete, K Henry, CT January, ... The Lancet 365 (9460), 682-686, 2005 | 212 | 2005 |
| Risk of cancers during interrupted antiretroviral therapy in the SMART study MJ Silverberg, J Neuhaus, M Bower, D Gey, A Hatzakis, K Henry, ... Aids 21 (14), 1957-1963, 2007 | 196 | 2007 |
| Indinavir concentrations and antiviral effect EP Acosta, K Henry, L Baken, LM Page, CV Fletcher Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19 (6 …, 1999 | 194 | 1999 |
| Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials M Nelson, K Arastéh, B Clotet, DA Cooper, K Henry, C Katlama, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 40 (4), 404-412, 2005 | 189 | 2005 |
| Concentration-controlled compared with conventional antiretroviral therapy for HIV infection CV Fletcher, PL Anderson, TN Kakuda, TW Schacker, K Henry, CR Gross, ... Aids 16 (4), 551-560, 2002 | 187 | 2002 |
| High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy KE Mondy, J Gottdiener, ET Overton, K Henry, T Bush, L Conley, ... Clinical Infectious Diseases 52 (3), 378-386, 2011 | 186 | 2011 |
| Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000–2010 K Buchacz, B Lau, Y Jing, R Bosch, AG Abraham, MJ Gill, MJ Silverberg, ... The Journal of infectious diseases 214 (6), 862-872, 2016 | 183 | 2016 |
| Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy RW Price, CT Yiannoutsos, DB Clifford, L Zaborski, A Tselis, JJ Sidtis, ... Aids 13 (13), 1677-1685, 1999 | 179 | 1999 |
| The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group PA Volberding, SW Lagakos, JM Grimes, DS Stein, HH Balfour, ... Jama 272 (6), 437-442, 1994 | 176 | 1994 |
